What we really want to know about neuro-ophthalmic sarcoid is when we face a newly diagnosed case, what is the optimal treatment to use? And if the patient breaks through this therapy, what should we turn to next? And how long do we have to maintain the patient on therapy? Sadly, we cannot, at this time, answer these key questions with level three evidence for neuro-ophthalmic sarcoid. The incidence of the disease is too rare, and virtually all studies have been single institution studies, for anyone to have approached the number of cases requisite for a proper two armed prospective study.
Date
2013
Language
eng
Format
video/mp4
Type
Image/MovingImage
Source
2013 North American Neuro-Ophthalmology Society Annual Meeting
